Readers interested in obesity and liver health will find a news summary of newly presented clinical research on a dual-receptor injectable.
Key Takeaways
- Randomized, double-blind, placebo-controlled phase 3 trial evaluated the weekly dual agonist
- Participants lost up to 16.6% of body weight while muscle mass was preserved
- Treatment reduced visceral fat by up to 34% and liver fat by 63.1%